SVP of Nonclinical & Clinical Development
Dr. Dean Wenham is an experienced drug developer and life science entrepreneur. After completing a PhD in Pharmacology at University College London in GPCR’s and signal transduction, Wenham has worked as a drug developer at both large pharmaceutical companies (Pfizer and AstraZeneca) as well as small biotechs. He leveraged this valuable pharma industry experience to launch InSymbiosis in 2005 as a platform to improve the costs, timelines, and overall efficiency of the drug development process and served as their CEO. Wenham went on to launch InSynchrony Ventures as an early stage investment platform for biopharma.
Wenham joined Camargo in 2019 following their acquisition of InSymbiosis, and is now focused on marrying the innovative InSymbiosis platform with Camargo’s leading regulatory and pharmaceutical development expertise to help biopharma navigate the complex nonclinical and early clinical drug development process.